Forgetta, Vincenzo http://orcid.org/0000-0002-6061-4720
Jiang, Lai
Vulpescu, Nicholas A.
Hogan, Megan S.
Chen, Siyuan
Morris, John A.
Grinek, Stepan
Benner, Christian
Jang, Dong-Keun
Hoang, Quy
Burtt, Noel
Flannick, Jason A.
McCarthy, Mark I.
Fauman, Eric
Greenwood, Celia M. T.
Maurano, Matthew T.
Richards, J. Brent
Funding for this research was provided by:
cihr
frq
Article History
Received: 15 June 2021
Accepted: 15 January 2022
First Online: 11 February 2022
Conflict of interest
: EF is an employee of Pfizer. MIM has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. MIM is currently at Genentech, 1 DNA Way, South San Francisco, CA 94080, and a holder of Roche stock. JBR has served as an advisor to GlaxoSmithKline and Deerfield Capital. JBR’s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. JBR is the CEO of 5 Prime Sciences (ExternalRef removed). VF is an employee of 5 Prime Sciences.